seizures in mice. Pol. J.
Pharmacol., 52, 477-480 (2000).
8. Thomson, A. M., Glycine modulation of the NMDA
receptor/channel complex. Trends Neurosci., 12,
349-353 (1989).
9. Collingridge, G. L., and
35. Jordan, V.C. Breast Cancer Research and
Treatment, 2, 123, (1982) (review).
36. Buckley, M.M.T. and Goa, K.L. Drugs 27, 451,
(1989) (review).
37. Duax, W.L. et al. Environmental Health
further study of the protein.49-52
Sigma Prod. No. I6125 is reagent grade. Product no.
I1149 has been additionally tested for trace metal
content.
I C H 2 C N H 2
O
further study of the protein.49-52
Sigma Prod. No. I6125 is reagent grade. Product no.
I1149 has been additionally tested for trace metal
content.
I C H 2 C N H 2
O
Res. Commun.,
44(3), 711-716 (1971).
2. Schmidt, J., and Raftery, M. A., A Simple Assay
for the Study of Solubilized Acetylcholine
Receptors. Anal. Biochem., 52(2), 349-354 (1973).
3. Utkin, Yu. N.
and Tweten, R.K., Purification of
Staphylococcal Enterotoxins. Meth. Enzymol., 165,
43-52 (1988).
2. Jenkinson, E.J. et al., Antigen-induced Apoptosis in
Developing T cells: a Mechanism for Negative
Acta., 381(2), 443-447 (1975).
6. Takagaki, K., et al., Preparation and application of
a fluorogenic substrate for endo-β-xylosidase.
J. Biochem. Biophys. Methods, 19(2-3), 207-214
(1989).
7.
butyrylcholinesterases. J. Pharmacol. Exp.
Ther., 249, 194-202 (1989).
6. Brocks, D. R., and Maboudian-Esfahani, M.,
7. J. Pharm. Pharmaceut. Sci., 2, 23-29 (1999).
HLD/JRC 10/03
Sigma brand
myelin
basic protein variants in various regions of pig
nervous system. J. Neurochem., 52, 736-740
(1989).
2. Sanghera, J. et al., Identification of the sites in
myelin basic protein that are phosphorylated
Cancer, 47, 811 (1991).
6. Borsi, L., et al., Int. J. Cancer, 52, 688 (1992).
7. Bourdon, M., and Ruoslahti, E., J. Cell Biol., 108,
1149 (1989).
8. Weller, A., et al., J. Cell Biol., 112, 355 (1991).
1985).
2. Hershko, A., et al., J. Biol. Chem., 257, 13964 (1-
982).
3. Perry, P.G., et al., Proc. Natl. Acad. Sci. USA, 84,
3033 (1987).
4. Perry, P.G., et al., J. Neurochem., 52, 1523 (1989).
5.
Biochem. 179,
11-16 (1989)
11. Aderem, A.A., Keum, M.M., Pure, E. and Cohn, Z.A., Proc. Natl. Acad. Sci. 83, 5817-5821 (1986)
12. Dziarski, R., Eur. J. Immunol. 19, 125-130 (1989)
13. Henrik Chart, Neil
Whittam, R., Biochem. J., 85:
495-507 (1962).
8. Swann, A.C. et al., J. Neurochem., 52: 1598-1604
(1989).
9. Kanzaki, A. et al., Brain Res., 569: 181-188 (1992).
10. Baker, R. et al., Cell
Whittam, R., Biochem. J., 85:
495-507 (1962).
8. Swann, A.C. et al., J. Neurochem., 52: 1598-1604
(1989).
9. Kanzaki, A. et al., Brain Res., 569: 181-188 (1992).
10. Baker, R. et al., Cell
Extra Pharmacopoeia, 29th ed.,
Reynolds, J. E. F., ed., The Pharmaceutical Press
(London, England: 1989), p. 963.
5. Ross, P. W., A new disinfectant, J. Clin. Pathol.,
19, 318-320 (1966).
6. Rubbo
Harbor Laboratory (Cold Spring Harbor, NY:
1989), pp. 1.6, A.6.
4. Analytical Profiles of Drug Substances, K. Florey,
ed., Academic Press (New York: 1973), Vol. 2, pp.
1-61.
5. Gallelli, J. F., Stability
Harbor Laboratory (Cold Spring Harbor, NY: 1989),
pp. 1.6, A.6.
4. Analytical Profiles of Drug Substances, K. Florey,
ed., Academic Press (New York: 1973), Vol. 2, pp.
1-61.
5. Gallelli, J.F., Stability
al., Clin. Exp. Immunol., 54, 327 (1983).
Sattentau, Q., et al., Cell, 52, 631 (1988).
Viellette, A., et al., Nature, 338, 257 (1989).
Sigma warrants that its products conform to the information contained